EDGAR·FLOW

Equillium, Inc. — Form 8-K

Filed November 12, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Equillium (market cap ~$7.1M) closed a $20M second tranche of a previously announced private placement on October 26, 2026, triggered by first patient dosing in the Phase 1 clinical trial of EQ504, an aryl hydrocarbon receptor modulator. Cash position of $53.3M as of September 30, 2026, rises to ~$72M pro forma post-October funding, with runway into 2029. Proof-of-mechanism data expected Q2 2027; proof-of-concept ulcerative colitis study planned for H2 2027.
Why this rating

Financing of $20M represents 280% of company market cap—critical lifeline. Phase 1 initiation and extended runway to 2029 validates clinical strategy and reduce near-term dilution risk.

Tradability signal
NO TRADE

No trade: only ~$46k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.34 ▲ 1.52%
at our read · unknown
$1.32
+10 min · unknown
$1.36 ▲ 3.03%
+30 min · unknown
$1.31 ▼ 0.76%
+1 hr · unknown
$1.29 ▼ 2.27%
+4 hrs · unknown
$1.27 ▼ 3.79%

The stock had already moved -1.49% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ EQ · stock on Yahoo Finance ↗

See more from November 12, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.